- Email: [email protected]
Proper indications for fertility-sparing surgery in young patients with early stage epithelial ovarian cancer
S96
Abstracts / Gynecologic Oncology 125 (2012) S3–S167
228 Proper indications for fertility-sparing surgery in young patients with early stage epithelial ovarian cancer J. Park, D. Kim, Y. Kim, J. Kim, Y. Kim, J. Nam. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Objective: To evaluate the safety of fertility-sparing surgery (FSS) in young patients (≤40 years) with stage I epithelial ovarian cancer by comparing with radical surgery (RS). Methods: Patients were categorized into four disease categories (stage IA and grade 1 or 2, n = 37 and 45 [RS and FSS]; stage IA and grade 3, n = 18 and 31 [RS and FSS]; stage IC and grade 1 or 2, n = 30 and 33 [RS and FSS]; and stage IC and grade 3, n = 20 and 25 [RS and FSS]). Clear cell carcinoma was regarded as grade 3 disease. Diseasefree survival (DFS) and overall survival (OS) were compared between fertility-sparing surgery and radical surgery in each disease categories. Results: There were no significant differences in clinicopathologic characteristics between RS and FSS groups in each disease categories. The median follow-up time was 79 months (range, 8–252 months). There were no differences in 5-year DFS (82% vs. 80%, P = 0.805) and OS (86% vs. 89%, P = 0.514) between RS and FSS groups. In subgroup with stage IA and grade 1 or 2 disease, 5-year DFS was 91% vs. 89% (RS vs. FSS) (P = 0.777), respectively, and 5-year OS was 97% vs. 97% (P = 0.951), respectively. In subgroup with stage IA and grade 3 disease, 5-year DFS was 87% vs. 83%, respectively (P = 0.770), and 5year OS was 94% vs. 89% (0.853), respectively. In subgroup with stage IC and grade 1 or 2 disease, 5-year DFS was 69% vs. 71% (P = 0.709), respectively, and 5-year OS was 73% vs. 76% (P = 0.870), respectively. In subgroup with stage IC and grade 3 disease, 5-year DFS were 72% and 70% (P = 0.565), respectively, and 5-year OS were 77% and 81% (P = 0.641), respectively. Conclusions: Fertility-sparing surgery can be performed without compromise of disease-free and overall survival in young patients with stage I epithelial ovarian cancer regardless of sub-stage and grade of disease. doi:10.1016/j.ygyno.2011.12.229
229 Nanofluidic technologies identify clinical features of neoadjuvant treatment and outcomes in ovarian cancer S. Shahabi, M. Mariani, A. Wilmot, R. Samuelson, C. Ferlini. Danbury Hospital, Danbury, CT.
doi:10.1016/j.ygyno.2011.12.228
Objective: Neoadjuvant chemotherapy is used in the treatment of advanced ovarian cancer. In this study, we determined the impact of chemotherapy on gene and microRNA (miRNA), expression in ovarian cancer specimens using nanofluidic technology. We performed the validation of this technique by using RNA extraction from archival formalin-fixed paraffin-embedded tissue. Molecular pathways involved in prediction of the outcome in new adjuvant patients were analyzed. Methods: Seventy-eight consecutive patients with advanced ovarian cancer who were treated with primary surgical debulking versus neoadjuvant chemotherapy (15/78) were investigated. All neoadjuvant patients were treated with combination platinum and Taxol. A chip 48.48 served to analyze a panel of 96 potential predictors of the outcome and response to chemotherapy. All the samples were normalized for multiple housekeeping genes and as consistent reference the ovarian cancer cell line A2780 was used. When needed for the analysis each factor was then categorized as high and low expression using the mean value as cutoff. Overall survival was analyzed using the methods of Kaplan and Meier and comparisons between groups by log-rank and Wilcoxon test.
Abstracts / Gynecologic Oncology 125 (2012) S3–S167
228 Proper indications for fertility-sparing surgery in young patients with early stage epithelial ovarian cancer J. Park, D. Kim, Y. Kim, J. Kim, Y. Kim, J. Nam. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea. Objective: To evaluate the safety of fertility-sparing surgery (FSS) in young patients (≤40 years) with stage I epithelial ovarian cancer by comparing with radical surgery (RS). Methods: Patients were categorized into four disease categories (stage IA and grade 1 or 2, n = 37 and 45 [RS and FSS]; stage IA and grade 3, n = 18 and 31 [RS and FSS]; stage IC and grade 1 or 2, n = 30 and 33 [RS and FSS]; and stage IC and grade 3, n = 20 and 25 [RS and FSS]). Clear cell carcinoma was regarded as grade 3 disease. Diseasefree survival (DFS) and overall survival (OS) were compared between fertility-sparing surgery and radical surgery in each disease categories. Results: There were no significant differences in clinicopathologic characteristics between RS and FSS groups in each disease categories. The median follow-up time was 79 months (range, 8–252 months). There were no differences in 5-year DFS (82% vs. 80%, P = 0.805) and OS (86% vs. 89%, P = 0.514) between RS and FSS groups. In subgroup with stage IA and grade 1 or 2 disease, 5-year DFS was 91% vs. 89% (RS vs. FSS) (P = 0.777), respectively, and 5-year OS was 97% vs. 97% (P = 0.951), respectively. In subgroup with stage IA and grade 3 disease, 5-year DFS was 87% vs. 83%, respectively (P = 0.770), and 5year OS was 94% vs. 89% (0.853), respectively. In subgroup with stage IC and grade 1 or 2 disease, 5-year DFS was 69% vs. 71% (P = 0.709), respectively, and 5-year OS was 73% vs. 76% (P = 0.870), respectively. In subgroup with stage IC and grade 3 disease, 5-year DFS were 72% and 70% (P = 0.565), respectively, and 5-year OS were 77% and 81% (P = 0.641), respectively. Conclusions: Fertility-sparing surgery can be performed without compromise of disease-free and overall survival in young patients with stage I epithelial ovarian cancer regardless of sub-stage and grade of disease. doi:10.1016/j.ygyno.2011.12.229
229 Nanofluidic technologies identify clinical features of neoadjuvant treatment and outcomes in ovarian cancer S. Shahabi, M. Mariani, A. Wilmot, R. Samuelson, C. Ferlini. Danbury Hospital, Danbury, CT.
doi:10.1016/j.ygyno.2011.12.228
Objective: Neoadjuvant chemotherapy is used in the treatment of advanced ovarian cancer. In this study, we determined the impact of chemotherapy on gene and microRNA (miRNA), expression in ovarian cancer specimens using nanofluidic technology. We performed the validation of this technique by using RNA extraction from archival formalin-fixed paraffin-embedded tissue. Molecular pathways involved in prediction of the outcome in new adjuvant patients were analyzed. Methods: Seventy-eight consecutive patients with advanced ovarian cancer who were treated with primary surgical debulking versus neoadjuvant chemotherapy (15/78) were investigated. All neoadjuvant patients were treated with combination platinum and Taxol. A chip 48.48 served to analyze a panel of 96 potential predictors of the outcome and response to chemotherapy. All the samples were normalized for multiple housekeeping genes and as consistent reference the ovarian cancer cell line A2780 was used. When needed for the analysis each factor was then categorized as high and low expression using the mean value as cutoff. Overall survival was analyzed using the methods of Kaplan and Meier and comparisons between groups by log-rank and Wilcoxon test.